CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We cut our target to $110 from $136, 12.5x our 2027 EPS view. We cut our 2026 EPS view to $6.46 from $6.54. We keep our 2027 EPS view at $8.82. We reaffirmed our fundamental outlook for the health care equipment sub-industry for the next 12 months as neutral. While we anticipate continued growth in elective procedures and diagnostics, we see tariffs and rising costs as considerable pressure points on profitability, especially for smaller firms in our coverage. TFX faced severe margin compression in Q1, with adj. gross margin and operating margin declining by 470 bps and 510 bps, respectively. This pressure, led by tariffs, higher logistics costs, the dilutive impact of the Vascular acquisition, and a quality remediation charge for a recall, led to a 3.5% Y/Y decrease in EPS. Compounding these challenges, the key Interventional segment (37% of total) posted modest 3% growth due to disruption from its sales force integration, and we are concerned the supplier recall may lead to elevated backorders in Q2.